A Phase Ib, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PMG1015 Injection After Multiple Ascending Doses in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 28 May 2024
Price :
$35 *
At a glance
- Drugs PMG 1015 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pulmongene
- 28 May 2024 Planned number of patients changed from 30 to 28.
- 13 Jun 2023 New trial record